Yusuf Menda
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Yusuf Menda sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Yusuf Menda: 3 sponsored US clinical trials, none currently recruiting.
Yusuf Menda sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neuroendocrine Tumor Grade 1, with 1 trials.
Upper-quartile sponsor footprint
Yusuf Menda sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
NCT05111509
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
NCT03335670
A Safety Study of 212Pb-Pentixather Radioligand Therapy
NCT05557708
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Therapeutic Areas
How the Yusuf Menda early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Neuroendocrine Tumor Grade 1 (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Yusuf Menda: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Yusuf Menda sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Yusuf Menda page
3 registered trials is a research-attention snapshot, not an endorsement of Yusuf Menda or any single study.
- None of Yusuf Menda's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Neuroendocrine Tumor Grade 1 is the condition Yusuf Menda studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neuroendocrine Tumor Grade 1 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yusuf Menda pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.